Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL475955 | 1.00 | LMNA (0.36) | LMNANPSR1GLO1CA2ALDH1A1 | |
| SCHEMBL3218626 | 1.00 | LMNA (0.36) | LMNANPSR1GLO1CA2ALDH1A1 | |
| SCHEMBL3218630 | 1.00 | LMNA (0.36) | LMNANPSR1GLO1CA2ALDH1A1 | |
| SCHEMBL5036637 | 0.89 | NPSR1 (0.43) | LMNANPSR1GLO1CA2ALDH1A1 | |
| SCHEMBL13482824 | 0.85 | LMNA (0.34) | LMNANPSR1GLO1CA2ALDH1A1 | |
| SCHEMBL13482836 | 0.85 | LMNA (0.34) | LMNANPSR1GLO1CA2ALDH1A1 | |
| SCHEMBL12157202 | 0.85 | LMNA (0.34) | LMNANPSR1GLO1CA2ALDH1A1 | |
| SCHEMBL15763405 | 0.85 | CA2 (0.33) | CA2 | |
| SCHEMBL4421280 | 0.85 | NPSR1 (0.40) | LMNANPSR1GLO1ALDH1A1KDM4E | |
| SCHEMBL3683013 | 0.83 | CA2 (0.34) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2084174-B1 | PREPARATION OF NUCLEOSIDES RIBOFURANOSYL PYRIMIDINES | GILEAD PHARMASSET LLC (US) | 2013-07-31 | — | — | EP | claimed |
| US-20100056770-A1 | PREPARATION OF NUCLEOSIDES RIBOFURANOSYL PYRIMIDINES | GILEAD PHARMASSET LLC | 2010-03-04 | — | — | US | claimed |
| EP-2084174-A1 | PREPARATION OF NUCLEOSIDES RIBOFURANOSYL PYRIMIDINES | Pharmasset, Inc. (US) | 2009-08-05 | — | — | EP | claimed |
| WO-2008045419-A1 | PREPARATION OF NUCLEOSIDES RIBOFURANOSYL PYRIMIDINES | PHARMASSET, INC. (US) | 2008-04-17 | — | — | WO | claimed |
| US-20230167151-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-01 | — | — | US | disclosed |
| US-20230167151-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-01 | — | — | US | disclosed |
| CN-109206396-B | Preparation method of 2-C-methyl-4,5-O- (1-methylvinyl) -D-arabinonic acid ethyl ester | 上海迪赛诺化学制药有限公司 | 2023-03-28 | — | — | CN | disclosed |
| EP-2909209-B1 | 2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC (US) | 2022-08-03 | — | — | EP | disclosed |
| EP-3912984-A1 | 4'-FLUORO-NUCLEOSIDES, 4'-FLUORO-NUCLEOTIDES AND ANALOGS THEREOF FOR THE TREATMENT OF HCV | Janssen BioPharma, Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| US-20210139523-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. (US) | 2021-05-13 | — | — | US | disclosed |
| EP-3797782-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF FOR USE IN THE TREATMENT OF VIRAL INFECTIONS | Janssen BioPharma, Inc. (US) | 2021-03-31 | — | — | EP | disclosed |
| EP-3160476-B1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF FOR USE IN THE TREATMENT OF VIRAL INFECTION | JANSSEN BIOPHARMA INC (US) | 2020-09-30 | — | — | EP | disclosed |
| US-20100056770-A1 | PREPARATION OF NUCLEOSIDES RIBOFURANOSYL PYRIMIDINES | GILEAD PHARMASSET LLC | 2010-03-04 | — | — | US | disclosed |
| US-20100048917-A1 | PREPARATION OF ALKYL-SUBSTITUTED 2-DEOXY-2-FLUORO-D-RIBOFURANOSYL PYRIMIDINES AND PURINES AND THEIR DERIVATIVES | PHARMASSETT, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-7601820-B2 | Preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidines and purines and their derivatives | PHARMASSET, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601820-B2 | Preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidines and purines and their derivatives | PHARMASSET, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| EP-2084174-A1 | PREPARATION OF NUCLEOSIDES RIBOFURANOSYL PYRIMIDINES | Pharmasset, Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20080139802-A1 | Converting 2'-deoxy-2'-fluoro-2'-methyl-D-ribonolactones derivatives to 3-fluoro-3-methyl-2-chlorofuran compounds using chlorinating agent such as sulfuryl chloride, thionyl chloride or phosphorus oxychloride and tetrabutylammonium bromide | PHARMASSET, INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139802-A1 | Converting 2'-deoxy-2'-fluoro-2'-methyl-D-ribonolactones derivatives to 3-fluoro-3-methyl-2-chlorofuran compounds using chlorinating agent such as sulfuryl chloride, thionyl chloride or phosphorus oxychloride and tetrabutylammonium bromide | PHARMASSET, INC. | 2008-06-12 | — | — | US | disclosed |
| WO-2008045419-A1 | PREPARATION OF NUCLEOSIDES RIBOFURANOSYL PYRIMIDINES | PHARMASSET, INC. (US) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048917-A1 | PREPARATION OF ALKYL-SUBSTITUTED 2-DEOXY-2-FLUORO-D-RIBOFURANOSYL PYRIMIDINES AND PURINES AND THEIR DERIVATIVES | NSUN2, FBL, UMPS | LMNA 633/4885NPSR1 3919/4885GLO1 3487/4885 |
| US-20230167151-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | LMNA 2079/4885NPSR1 1545/4885GLO1 3370/4885 |
| US-20080139802-A1 | Converting 2'-deoxy-2'-fluoro-2'-methyl-D-ribonolactones derivatives to 3-fluoro-3-methyl-2-chlorofuran compounds using chlorinating agent such as sulfuryl chloride, thionyl chloride or phosphorus oxychloride and tetrabutylammonium bromide | FBL, NSUN2, RNGTT | LMNA 3568/4885NPSR1 3725/4885GLO1 2382/4885 |
| US-20100056770-A1 | PREPARATION OF NUCLEOSIDES RIBOFURANOSYL PYRIMIDINES | RNGTT, UMPS, NT5C3B | LMNA 3790/4885NPSR1 2359/4885GLO1 4124/4885 |
| US-20210139523-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | LMNA 2079/4885NPSR1 1545/4885GLO1 3370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.